Definitive Healthcare Corp. (NASDAQ:DH) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its stake in Definitive Healthcare Corp. (NASDAQ:DH) by 6.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 542,170 shares of the company’s stock after purchasing an additional 33,161 shares during the period. Victory Capital Management Inc. owned about 0.46% of Definitive Healthcare worth $2,424,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 272 Capital LP acquired a new stake in shares of Definitive Healthcare during the 2nd quarter worth about $3,480,000. Vanguard Group Inc. increased its holdings in shares of Definitive Healthcare by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,535,377 shares of the company’s stock valued at $36,600,000 after purchasing an additional 67,068 shares in the last quarter. Boston Partners purchased a new position in Definitive Healthcare in the 1st quarter valued at approximately $550,000. Marshall Wace LLP purchased a new position in shares of Definitive Healthcare in the second quarter valued at $1,535,000. Finally, Millennium Management LLC purchased a new position in Definitive Healthcare during the 2nd quarter valued at about $9,283,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Trading Up 2.8 %

Shares of Definitive Healthcare stock opened at $4.37 on Monday. Definitive Healthcare Corp. has a fifty-two week low of $3.19 and a fifty-two week high of $10.62. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a market cap of $504.84 million, a price-to-earnings ratio of -1.41, a price-to-earnings-growth ratio of 3.13 and a beta of 1.33. The business has a fifty day simple moving average of $4.35 and a 200-day simple moving average of $4.81.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Barclays reduced their price target on Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Friday, November 8th. Robert W. Baird lowered their target price on Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Stifel Nicolaus reduced their price objective on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Finally, BTIG Research assumed coverage on shares of Definitive Healthcare in a report on Tuesday, September 17th. They issued a “buy” rating and a $7.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.81.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.